Pharmacokinetics of calcium ketohomopantothenate — A new neurotropic drug

N. M. Nasybullina; V. P. Zherdev; V. I. Gunar; A. K. Sariev; G. S. Kozlova; A. L. Karaev

doi:10.1007/bf02218823

Pharmacokinetics of calcium ketohomopantothenate — A new neurotropic drug

Pharmaceutical Chemistry Journal ◽

10.1007/bf02218823 ◽

1996 ◽

Vol 30 (12) ◽

pp. 737-738

Author(s):

N. M. Nasybullina ◽

V. P. Zherdev ◽

V. I. Gunar ◽

A. K. Sariev ◽

G. S. Kozlova ◽

...

Keyword(s):

Neurotropic Drug

Download Full-text

Transcallosal response (TCR) in the chronic photosensitive baboon preparation, Papio papio. I. Premotor cortical stimulation, recovery cycle and neurotropic drug effect

Electroencephalography and Clinical Neurophysiology ◽

10.1016/0013-4694(87)90058-7 ◽

1987 ◽

Vol 67 (6) ◽

pp. 556-563 ◽

Cited By ~ 4

Author(s):

Hiroshi Baba ◽

Juhn A. Wada

Keyword(s):

Drug Effect ◽

Cortical Stimulation ◽

Recovery Cycle ◽

Neurotropic Drug ◽

Transcallosal Response ◽

Papio Papio

Download Full-text

Short report of original clinical trial of neurotropic drug: L-dopa efficiency of using in therapy of coronary artery disease

Pharmaceutics and Pharmacology Research ◽

10.31579/2693-7247/011 ◽

2021 ◽

Vol 4 (1) ◽

pp. 01-03

Author(s):

Irina V Okunevich

Keyword(s):

Risk Factors ◽

Coronary Artery Disease ◽

Coronary Artery ◽

Well Being ◽

Atherogenic Dyslipidemia ◽

Short Report ◽

Complex Therapy ◽

Neurotropic Drug ◽

Hypolipidemic Property ◽

Artery Disease

The short clinical study is devoted to the corrective action of the neurotropic drug LEVOPA (L-DOPA) in patients with coronary artery disease (CAD) complicated by atherogenic dyslipidemia (DLP), moderate angina pectoris (AP), arterial hypertension (AH) and other risk factors for the development of atherosclerosis (AS). Purposefully in neurology, drug of L-DOPA - LEVOPA is used in significant doses (3-10 g/day) to treat Parkinson's disease, including atherosclerotic genesis. In this study, the neurotropic drug LEVOPA was used as an active metabolic agent in the complex therapy of CAD in a small dose of 0.5 g 3 times a day, with chronic oral administration for 4 weeks. As a result, an improvement in the lipid profile of blood and the hypolipidemic property of the drug LEVOPA were found. An improvement in hemodynamics and general well-being was noted in treated patients with aggravating risk factors for the development of AS. We had notice the decrease of lipid peroxidation (LPO) too.

Download Full-text